




RealRate

PHARMACEUTICAL 2024

Decoy Therapeutics Inc
Rank 207 of 309



RealRate

The First AI Rating Agency

www.realrate.ai

Decoy Therapeutics Inc Rank 207 of 309

The relative strengths and weaknesses of Decoy Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Decoy Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 17% points. The greatest weakness of Decoy Therapeutics Inc is the variable Net Income, reducing the Economic Capital Ratio by 132% points.

The company's Economic Capital Ratio, given in the ranking table, is 140%, being 73% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	6,520
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	603
Liabilities, Non-Current	0
Other Assets	67
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	696
Other Net Income	352
Other Revenues	0
Property and Equipment	0
Research and Development	7,174
Selling, General and Administrative Expense	5,721

Output Variable	Value in 1000 USD
Assets	6,587
Liabilities	1,299
Expenses	12,895
Revenues	0
Stockholders Equity	5,287
Net Income	-12,543
Comprehensive Net Income	-12,543
BaseVar	10,566
ECR before LimitedLiability	-26%
Economic Capital Ratio	140%